Abstract
Caprolactam urea 1, identified as a weak Factor Xa inhibitor screening hit (IC50 = 16 μM), served as the starting point for a limited parallel-synthesis driven SAR study to improve potency. Remarkably, the corresponding thiourea analog 8c (IC50 = 0.11 μM) was 145-fold more potent against Factor Xa compared to 1. In general, caprolactam analogs containing a thiourea linker were significantly more potent than their corresponding urea counterparts, and it is hypothesized that this is partly due to a conformational preference of the thiourea linkage which facilitates binding of the terminal groups of the inhibitors to the Factor Xa S1/S4 pockets. Analog 8c was selective against a panel of related serine proteases. Upon intra-duodenal administration in rats, 8c dose-dependently increased prothrombin time ex vivo, and when dosed i.v., it demonstrated efficacy in a rat model of venous thrombosis. This thiourea lead series formed the basis for follow-on investigations to discover potent drug-like Factor Xa inhibitors using the caprolactam scaffold but employing suitable thiourea surrogates.
Keywords: Factor Xa, FXa inhibitor, caprolactam, serine protease
Letters in Drug Design & Discovery
Title: Initial Structure-Activity Relationships for a Caprolactam-based Series of Neutral Factor Xa Inhibitors: Lead Identification
Volume: 2 Issue: 8
Author(s): Gregory S. Bisacchi, Philip D. Stein, Jack Z. Gougoutas, Karen S. Hartl, R. Michael Lawrence, Eddie Liu, Andrew Pudzianowski, William A. Schumacher, Doree Sitkoff, Thomas E. Steinbacher, James Sutton, Zhaoxiao Zhang and Steven M. Seiler
Affiliation:
Keywords: Factor Xa, FXa inhibitor, caprolactam, serine protease
Abstract: Caprolactam urea 1, identified as a weak Factor Xa inhibitor screening hit (IC50 = 16 μM), served as the starting point for a limited parallel-synthesis driven SAR study to improve potency. Remarkably, the corresponding thiourea analog 8c (IC50 = 0.11 μM) was 145-fold more potent against Factor Xa compared to 1. In general, caprolactam analogs containing a thiourea linker were significantly more potent than their corresponding urea counterparts, and it is hypothesized that this is partly due to a conformational preference of the thiourea linkage which facilitates binding of the terminal groups of the inhibitors to the Factor Xa S1/S4 pockets. Analog 8c was selective against a panel of related serine proteases. Upon intra-duodenal administration in rats, 8c dose-dependently increased prothrombin time ex vivo, and when dosed i.v., it demonstrated efficacy in a rat model of venous thrombosis. This thiourea lead series formed the basis for follow-on investigations to discover potent drug-like Factor Xa inhibitors using the caprolactam scaffold but employing suitable thiourea surrogates.
Export Options
About this article
Cite this article as:
Bisacchi S. Gregory, Stein D. Philip, Gougoutas Z. Jack, Hartl S. Karen, Lawrence Michael R., Liu Eddie, Pudzianowski Andrew, Schumacher A. William, Sitkoff Doree, Steinbacher E. Thomas, Sutton James, Zhang Zhaoxiao and M. Seiler Steven, Initial Structure-Activity Relationships for a Caprolactam-based Series of Neutral Factor Xa Inhibitors: Lead Identification, Letters in Drug Design & Discovery 2005; 2 (8) . https://dx.doi.org/10.2174/157018005774717316
DOI https://dx.doi.org/10.2174/157018005774717316 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Metabolism of Anticancer Drugs by the Liver: Current Approaches to the Drug Development Process
Current Drug Metabolism Histamine H4 Receptor: A Novel Target for Inflammation Therapy
Mini-Reviews in Medicinal Chemistry Learning from Multiple Classifier Systems: Perspectives for Improving Decision Making of QSAR Models in Medicinal Chemistry
Current Topics in Medicinal Chemistry Rubiscolins - Highly Potent Peptides Derived from Plant Proteins
Mini-Reviews in Medicinal Chemistry High Mutation Rate Leads to Fitness Loss for Coronavirus Quasispecies
Coronaviruses The Antioxidant Activity of Coumarins and Flavonoids
Mini-Reviews in Medicinal Chemistry Clinical Pattern and Causality Assessment of Drug-induced Cutaneous Reactions in a Tertiary Care Hospital in India: A Prospective Study
Current Drug Safety Neglected Tropical Diseases (NTDs) and COVID-19 Pandemic in Africa: Special Focus on Control Strategies
Combinatorial Chemistry & High Throughput Screening Selective Histone Deacetylase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Subject Index to Volume 1
Medicinal Chemistry Reviews - Online (Discontinued) Study on the Influences of Palindromes in Protein Coding Sequences on the Folding Rates of Peptide Chains
Protein & Peptide Letters Recent Developments in Polymeric Nanoparticle Engineering and Their Applications in Experimental and Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry A Novel Triazole Nucleoside Suppresses Prostate Cancer Cell Growth by Inhibiting Heat Shock Factor 1 and Androgen Receptor
Anti-Cancer Agents in Medicinal Chemistry Anti-Inflammatory/Analgesic
Current Bioactive Compounds Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein 1: Recent Developments Concerning Substrates and Inhibitors of a Promising Therapeutic Target
Current Medicinal Chemistry Synthesis and Biological Evaluation of Novel β-Carboline Derivatives as Antiproliferative Agents
Letters in Drug Design & Discovery Descending Necrotizing Mediastinitis of Odontogenic Origin
Recent Patents on Anti-Infective Drug Discovery NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Biomedical Perspectives of Acute and Chronic Neurological and Neuropsychiatric Sequelae of COVID-19
Current Neuropharmacology DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry